408 related articles for article (PubMed ID: 28223335)
1. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
2. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Cell Tissue Res; 2013 Nov; 354(2):521-32. PubMed ID: 23881403
[TBL] [Abstract][Full Text] [Related]
3. Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
Wang G; Sheng W; Tang J; Li X; Zhou J; Dong M
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31898732
[TBL] [Abstract][Full Text] [Related]
4. Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53.
Wang G; Sheng W; Shi X; Li X; Zhou J; Dong M
FEBS J; 2019 May; 286(9):1668-1682. PubMed ID: 30724469
[TBL] [Abstract][Full Text] [Related]
5. Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1 pathway.
Zhou L; Sheng W; Jia C; Shi X; Cao R; Wang G; Lin Y; Zhu F; Dong Q; Dong M
J Cell Mol Med; 2020 Sep; 24(18):10560-10572. PubMed ID: 32779876
[TBL] [Abstract][Full Text] [Related]
6. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
7. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
[TBL] [Abstract][Full Text] [Related]
8. NUMB controls p53 tumour suppressor activity.
Colaluca IN; Tosoni D; Nuciforo P; Senic-Matuglia F; Galimberti V; Viale G; Pece S; Di Fiore PP
Nature; 2008 Jan; 451(7174):76-80. PubMed ID: 18172499
[TBL] [Abstract][Full Text] [Related]
9. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein.
Sheng W; Dong M; Chen C; Li Y; Liu Q; Dong Q
Oncotarget; 2017 Feb; 8(9):14359-14373. PubMed ID: 27092875
[TBL] [Abstract][Full Text] [Related]
10. A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
Colaluca IN; Basile A; Freiburger L; D'Uva V; Disalvatore D; Vecchi M; Confalonieri S; Tosoni D; Cecatiello V; Malabarba MG; Yang CJ; Kainosho M; Sattler M; Mapelli M; Pece S; Di Fiore PP
J Cell Biol; 2018 Feb; 217(2):745-762. PubMed ID: 29269425
[TBL] [Abstract][Full Text] [Related]
11. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
[TBL] [Abstract][Full Text] [Related]
12. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.
Guo K; Cui J; Quan M; Xie D; Jia Z; Wei D; Wang L; Gao Y; Ma Q; Xie K
Clin Cancer Res; 2017 Feb; 23(3):687-696. PubMed ID: 27449499
[TBL] [Abstract][Full Text] [Related]
13. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
[TBL] [Abstract][Full Text] [Related]
14. [The role of Gli1 in the invasion and migration of pancreatic cancer cells].
Sheng W; Dong M; Zhou J; Liu Q; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2014 Jul; 52(7):518-22. PubMed ID: 25262609
[TBL] [Abstract][Full Text] [Related]
15. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Wang W; Qin JJ; Voruganti S; Nijampatnam B; Velu SE; Ruan KH; Hu M; Zhou J; Zhang R
Cancer Res; 2018 Oct; 78(19):5656-5667. PubMed ID: 30217928
[TBL] [Abstract][Full Text] [Related]
17. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
[TBL] [Abstract][Full Text] [Related]
18. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Liu QF; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):916-21. PubMed ID: 24433772
[TBL] [Abstract][Full Text] [Related]
19. Progress in the research of p53 tumour suppressor activity controlled by Numb in triple-negative breast cancer.
Xian J; Cheng Y; Qin X; Cao Y; Luo Y; Cao Y
J Cell Mol Med; 2020 Jul; 24(13):7451-7459. PubMed ID: 32501652
[TBL] [Abstract][Full Text] [Related]
20. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
